Tadao Maeda1,2,3 and Masayo Takahashi1,2,3 1Research Center, Kobe City Eye Hospital, Kobe 6500-047, Japan 2Department of Ophthalmology, Kobe City Eye Hospital, Kobe 6500-047, Japan 3Vision Care Cell Therapy, Kobe 650-0047, Japan Correspondence: takahashisecvision-care.jp

Regenerative medicine is a great hope for patients suffering from diseases for which no effective treatment is available. With the creation of induced pluripotent stem cells (iPSCs) in 2006, research and development has accelerated expeditiously, reaching a practical stage worldwide. The iPSC-regenerative medicine in ophthalmology is one of the pioneers, which has kicked off clinical application ahead of other fields owing to its advantages. The clinical safety issues of iPSC-derived retinal pigment epithelial (iPSC-RPE) transplantation for exudative age-related macular degeneration have been addressed to a certain extent. Preparations are being made for the next clinical study based on the improvement of its therapeutic effects and expansion of indications globally. Steady progress toward the practical applications of regenerative medicine for the treatment of retinal disorders is expected in the future while strengthening global cooperation amid various research areas, clinical fields, and regulations.